文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤一线自体移植的利弊:时机之争

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.
PubMed 文献 · Blood · 2018-12-26

过去十年多发性骨髓瘤治疗格局因多类新药问世而显著改变,新药联合方案可长期控制疾病。在此背景下,本文综述一线自体造血干细胞移植(ASCT)的利弊与时机争议:近期3期试验再次证实ASCT的生存获益,回顾性研究显示首次复发时行ASCT亦可行,且ASCT使用存在美国与欧洲的地理差异,ASCT将继续作为增强其他治疗模式疗效的平台。

要点

  • 近期3期试验再次证实ASCT与多发性骨髓瘤生存获益相关。
  • 回顾性研究显示,首次复发时而非初始治疗时行ASCT具有可行性。
  • ASCT使用存在地理差异,尤其美国与欧洲在一线治疗中的使用不同。

核心结论

  • 近期3期试验再次证实ASCT与多发性骨髓瘤生存获益相关。
  • 回顾性研究显示首次复发时行ASCT而非作为初始治疗组成部分具有可行性。
  • ASCT将继续在多发性骨髓瘤管理中发挥重要作用,并可能作为增强目前正在开发的其他治疗模式疗效的平台。

研究设计与样本

  • 本文为综述,围绕一线自体造血干细胞移植(ASCT)在多发性骨髓瘤中的利弊与时机争议进行讨论。

主要发现

  • 过去十年多类新药问世,尤其多药联合时可长期有效控制疾病。
  • 在新药出现前,外周血自体造血干细胞移植是适合该操作患者的主要治疗,多数患者获得深度且持久的缓解。
  • 尽管有了更有效的治疗,ASCT仍在年轻患者的整体管理中发挥重要作用,并已与其他治疗方式整合以提供最大获益。
  • 近期3期试验再次证实ASCT在多发性骨髓瘤中的生存获益。
  • 回顾性研究显示,在首次复发时使用ASCT而非作为初始治疗组成部分具有可行性。

关键数值与推荐

  • ASCT的使用存在显著地理差异,尤其美国与欧洲在一线治疗中的使用不同。
  • 这些差异在很大程度上由初始治疗的药物及药物联合的可及性以及ASCT后维持治疗策略驱动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs, which are very effective at controlling the disease for prolonged periods of time, especially when used in multidrug combinations. Prior to the advent of these new agents, peripheral blood autologous stem cell transplantation (ASCT) was the mainstay of therapy for patients who were eligible to undergo the procedure, with deep and durable responses in the majority of patients. Despite the introduction of more effective therapies, ASCT continues to play an important role in overall management of younger patients, where it has been integrated with the other therapeutic approaches to provide maximum benefit. Recent phase 3 trials have once again confirmed the survival benefit associated with ASCT in myeloma. Retrospective studies have also demonstrated the feasibility of using ASCT at the time of first relapse rather than as a component of the initial treatment. Significant geographical variations exist in the use of ASCT, especially between the United States and Europe in terms of its use as part of upfront therapy. Much of these differences are driven by the availability of drugs and drug combinations for initial therapy of myeloma as well as maintenance approaches post-ASCT. It is amply clear from these trials that ASCT will continue to play an important role in management of myeloma and is likely to be used as a platform for enhancing the efficacy of other treatment modalities that are currently in development.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kumar SK, Buadi FK, Rajkumar SV, et al. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood. 2018. PMID: 30587528. doi:10.1182/blood-2018-08-825349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。